2상모집 중
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
연구 개요
The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before. The researchers think that a combination of axitinib and nivolumab may help people with this disease because both drugs target and block proteins that play a role in cancer cell survival and growth. The researchers think the drugs may be more effective if given in combination rather than on their own.
- 스폰서
- 협력: 화이자
- 적응증
- Mucosal Melanoma
- 중재
- Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
- 목표 등록
- 20명
- 시작일
- 2022-05-17
- 완료(예정)
- 2027-05-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.